EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of adjuvant chemotherapy of osteosarcoma with special reference to adriamycin (final report)



Evaluation of adjuvant chemotherapy of osteosarcoma with special reference to adriamycin (final report)



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(12): 3245-3251



Adjuvant chemotherapy mainly with ADR performed in 117 patients (pts) with primary osteosarcoma of the extremity for the purpose of preventing pulmonary metastasis after radical ablative surgery. The mean follow-up period for 117 pts was 51.7 months (range: 3 to 137), for 53 survivors, 90.1 months (range: 60 to 137) and for 64 decreased, 20.5 months (range: 3 to 73). ADR was administered intravenously with 0.6-0.8 mg/kg/day for 3 consecutive days at monthly intervals after surgery until reaching 600 or 500 mg/m2 of the total cumulative dose. Five-year overall and disease-free survival rate of all pts was 50.2% and 39.4%, respectively. Thirty-seven pts (multi-drug group) with the combination of ADR and HDMTX had a higher survival rate (63.1% in 5-year overall survival rate and 47.8% in 5-year disease-free survival rate) than that of 80 pts with ADR alone (ADR group) (44.4% in 5-year overall survival rate and 35.6% in 5-year disease-free survival rate). Five-year survival rate for 65 pts administered the greater than 500 mg of ADR was 59.3% compared to 36.9% for 52 pts the less than 500 mg (p less than 0.05). In 65 pts administered the greater than 500 mg of ADR, 5-year survival rate (76.5%) of the multidrug group (17 pts) showed superiority to that 52.1%) of the ADR group (48 pts) (p less than 0.01). Even in the multi-drug group, 5-year survival rate (76.5%) of 17 pts administered the greater than 500 mg of ADR was higher than that (41.3%) of 20 pts given the less than 500 mg (p less than 0.01). Distant metastases were recognized at lung in 52 pts (lung group), lung + extrapulmonary organs in 14 (+ extragroup), and only extrapulmonary organs in 3 (extra group). Five-year survival rate of 66 pts with pulmonary metastasis was 17.1% and 21.2% in the lung group compared with 0% of the extra group (P less than 0.01). Five-year survival rate for 23 pts treated with thoracotomy was 43.5% compared to 2.6% for 43 without it (p less than 0.01).

(PDF emailed within 1 workday: $29.90)

Accession: 040063268

Download citation: RISBibTeXText

PMID: 3196042



Related references

Randomized trial of adjuvant chemotherapy in osteogenic osteosarcoma: comparison of altering sequential administrations of high doses of adriamycin, methotrexate, and cyclophosphamide with a 6-month administration of high-dose adriamycin followed by a low-dose semicontinuous chemotherapy. EORTC Osteosarcoma Working Party Group. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 68: 28-32, 1978

Evaluation of chemotherapy in advanced urothelial carcinoma: with special reference to combination chemotherapy with adriamycin, cyclophosphamide and cisplatin (ACE chemotherapy). Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 78(2): 327-334, 1987

Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer. Hinyokika Kiyo. Acta Urologica Japonica 32(6): 795-802, 1986

Therapeutic experiences of cis diamminedichloroplatinum adriamycin and 5 fluorouracil combination chemotherapy in advanced urothelial cancer with special reference to the adjuvant chemotherapy in invasive urothelial cancer. Acta Urologica Japonica 32(6): 795-802, 1986

Treatment of osteosarcoma with maintenance of the affected extremity neoadjuvant chemotherapy with intraarterial cisplatinum and intravenous adriamycin including adjuvant chemotherapy. Oncologia (Madrid) 11(2): 80-87, 1988

Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. European Journal of Cancer and Clinical Oncology 22(11): 1337-1345, 1986

Adriamycin methotrexate high dose vs. adriamycin methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities a randomized study. European Journal of Cancer and Clinical Oncology 22(1): 1337-1346, 1986

Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. Journal of Cancer Research and Clinical Oncology 106 Suppl: 1-7, 1983

An evaluation of livestock management and production in Botswana, with special reference to communal areas: final report (Volume 2: main report). An evaluation of livestock management and production in Botswana, with special reference to communal areas: final report Volume 2: main report: xii + approx. 280, 1982

An evaluation of livestock management and production in Botswana, with special reference to communal areas: draft final report (3 vols.). An evaluation of livestock management and production in Botswana, with special reference to communal areas: draft final report 3 vols: 23; xii + 280; 206, 1981

Adjuvant chemotherapy in the treatment of primary soft tissue sarcomas, with special reference to intra-arterial infusion chemotherapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(9): 1729-1735, 1984

Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity: a 6 year report. Tumori 65(5): 587-600, 1979

Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation. Anticancer Research 22(5): 2765-2770, 2003

Evaluation of the atf low dose adriamycin plus tamoxifen plus tegafur therapy as adjuvant chemotherapy for breast cancer. Journal of Japan Society for Cancer Therapy 23(3): 728-733, 1988

Evaluation of the ATF (low dose adriamycin + tamoxifen + tegafur) therapy as adjuvant chemotherapy of breast cancer. Nihon Gan Chiryo Gakkai Shi 23(3): 728-733, 1988